Download PDF
Der Nuklearmediziner 2009; 32(2): 164-169
DOI: 10.1055/s-0028-1128128
Nicht-FDG-PET

© Georg Thieme Verlag KG Stuttgart · New York

Nuklearmedizinische Verfahren zum Nachweis hypoxischer Gewebe

Hypoxia ImagingR. Bares 1 , G. Reischl 2 , S.-M. Eschmann 3
  • 1Abteilung Nuklearmedizin, Universitätsklinikum Tübingen
  • 2Sektion Radiopharmazie, Universitätsklinikum Tübingen
  • 3Abteilung Nuklearmedizin, Marien-Hospital Stuttgart
Further Information

Publication History

Publication Date:
22 June 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hypoxie spielt in der Pathogenese zahlreicher Erkrankungen eine bedeutende Rolle. Während in vielen Fällen die Hypoxie klinisch bzw. durch indirekte Zeichen (z. B. Minderperfusion) diagnostiziert werden kann, ist dies bei malignen Tumoren nicht möglich. Neben der invasiven pO2-Histografie sind nuklearmedizinische Verfahren unter Verwendung radioaktiv markierter Hypoxiemarker der bislang einzige praktikable Ansatz. Bewährt haben sich vor allem 18F markierte Derivate des Nitroimidazols, die nach i. v. Injektion in die Zelle diffundieren und dort reduziert werden. Die entstehenden Intermediate binden unter hypoxischen Bedingungen an Makromoleküle in der Zelle und werden auf diese Weise retendiert, während bei Normoxie eine rasche Rückdiffusion erfolgt. In ersten klinischen Anwendungen konnte gezeigt werden, dass die lokale Anreicherung der Hypoxiemarker im Tumor mit einem schlechten Therapieansprechen verknüpft ist und somit konkrete Relevanz für die Therapieplanung bekommen könnte. Vor Aufnahme der Hypoxiebildgebung in die Planungsprotokolle der Radiotherapie sind jedoch größere prospektive Studien zur Überprüfung dieser ersten Ergebnisse erforderlich.

Abstract

Hypoxia plays an important role in the pathogenesis of many diseases. While it can be diagnosed clinically or assumed by indirect signs (reduced perfusion) in many instances, this cannot be achieved in malignant tumors. Besides invasive pO2-polarography nuclear medicine procedures are the only practical approach to detect tumor hypoxia so far. 18F labelled derivatives of nitroimidazole were shown to be suitable in both experimental and clinical studies. After iv injection they enter the cells via diffusion, are reduced, and finally bind to intracellular macromolecules, if hypoxia is present. In case of normoxia they rapidly leave the cells by rediffusion. First clinical studies demonstrated that local retention of hypoxia markers in malignant tumors was indicative for poor therapeutic outcome and may therefore gain relevance for treatment planning in the future. Prior to this, however, large prospective trials are needed to substantiate the first clinical results.

Schlüsselwörter

Hypoxie - Nitroimidazol - PET - Tumor - Radiotherapie

Key words

hypoxia - nitroimidazole - PET - tumor - radiotherapy

Literatur

  • 1 Barthel H, Wilson H, Collingridge DR. et al . In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography.  Br J Cancer. 2004;  90 2232-2242
    PubMedGoogle Scholar
  • 2 Bentzen L, Keiding S, Nordsmark M. et al . Tumor oxygenation assessed by [18F] fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumors.  Radiother Oncol. 2003;  67 339-344
    CrossrefPubMedGoogle Scholar
  • 3 Biaglow R, Varnes ME, Roizen-Towle L. et al . Biochemistry of Reduction of Nitro Heterocycles.  Biochem Pharmacol. 1986;  35 77-90
    CrossrefPubMedGoogle Scholar
  • 4 Brizel DM, Dodge RK, Clough RW. et al . Oxygenation of head and neck cancer: chnages during radiotherapy and impact on treatment outcome.  Radiother Oncol. 1999;  53 113-117
    CrossrefPubMedGoogle Scholar
  • 5 Caldwell JH, Revenaugh JR, Martin GV. et al . Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia.  J Nucl Med. 1995;  36 1633-1638
    PubMedGoogle Scholar
  • 6 Chao KS, Bosch WR, Mutic S. et al . A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.  Int J Radiat Oncol Biol Phys. 2001;  49 1171-1182
    CrossrefPubMedGoogle Scholar
  • 7 Chapman JD. Hypoxic sensitizers – implications for radiation therapy.  N Engl J Med. 1979;  301 1429-1432
    PubMedGoogle Scholar
  • 8 Dehdashti F, Grigsby PW, Mintun MA. et al . Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.  Int J Radiat Oncol Biol Phys. 2003;  55 1233-1238
    CrossrefPubMedGoogle Scholar
  • 9 Dietz DW, Dehdashti F, Grigsby PW. et al . Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.  Dis Colon Rectum. 2008;  51 1641-1648
    CrossrefPubMedGoogle Scholar
  • 10 Dubois L, Landuyt W, Haustermans K. et al . Evaluation of hypoxia in an experimental rat tumour model by [18F]fluoromisonidazole PET and immunohistochemistry.  Br J Cancer. 2004;  91 1947-1954
    CrossrefPubMedGoogle Scholar
  • 11 Endrich B, Vaupel P. Blood perfusion and microenvironment of human tumors. Springer 1988
  • 12 Eschmann SM, Paulsen F, Reimold M. et al . Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.  J Nucl Med. 2005;  46 253-260
    PubMedGoogle Scholar
  • 13 Gagel B, Piroth M, Pinkawa M. et al . pO polarography, contrast enhanced color duplex sonography (CDS) [18F], fluoromisonidazole und [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relavant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?.  BMC Cancer. 2007;  7 113
    CrossrefPubMedGoogle Scholar
  • 14 Grönroos T, Eskola O, Lehtio K. et al . Pharmacokinetics of [18F]FETNIM: a potential marker for PET.  J Nucl Med. 2001;  42 1397-1404
    PubMedGoogle Scholar
  • 15 Grönroos T, Bentzen L, Marjamaka P. et al . Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.  Eur J Nucl Med Mol Imaging. 2004;  31 513-520
    CrossrefPubMedGoogle Scholar
  • 16 Groshar D, McEwan AJ, Parliament MB. et al . Imaging tumor hypoxia and tumor perfusion.  J Nucl Med. 1993;  34 885-888
    PubMedGoogle Scholar
  • 17 Höckel M, Vaupel P. Biological consequences of tumor hypoxia.  Sem Oncol. 2001;  28 36-41
    PubMedGoogle Scholar
  • 18 Kumar P, Wiebe LI, Atrazheva E. et al . An improved synthesis of α-AZA, α-AZP and α-AZG, the precursors to clinical markers of tissue hypoxia.  Tetrahedron Lett. 2001;  42 2077-2078
    CrossrefPubMedGoogle Scholar
  • 19 Kumar P, Wiebe LI, Asikoglu M. et al . Microwave-assisted (radio)halogena-tion of nitroimidazole-based hypoxia markers.  Appl Radiat Isot. 2002;  57 697-703
    CrossrefPubMedGoogle Scholar
  • 20 Kumar P, McQuarrie SA, Zhou A. et al . 131I]Iodoazomycin arabinoside for low-dose-rate isotope radiotherapy: radiolabeling, stability, long-term whole-body clearance and radiation dosimetry estimates in mice.  Nucl Med Biol. 2005;  32 647-653
    CrossrefPubMedGoogle Scholar
  • 21 Lewis JS, Sharp TL, Laforest R. et al . Tumor uptake of copper-diacetyl-bis(N4-methylsemicarbazone): Effect of changes in tissue oxygenation.  J Nucl Med. 2001;  42 655-661
    PubMedGoogle Scholar
  • 22 Mannan RH, Somayaji VV, Lee J. et al . Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia.  J Nucl Med. 1991;  32 1764-1770
    PubMedGoogle Scholar
  • 23 Maurer RI, Blower PJ, Dilworth JR. et al . Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals.  J Med Chem. 2002;  45 1420-1431
    CrossrefPubMedGoogle Scholar
  • 24 Nordsmark M, Bentzen SM, Rudat V. et al . Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.  Radiother Oncol. 2005;  77 18-24
    CrossrefPubMedGoogle Scholar
  • 25 O’Donoghue JA, Zanzonico P, Pugachev A. et al . Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring MicroPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.  Int J Radiat Oncol Biol Phys. 2005;  61 1493-1502
    CrossrefPubMedGoogle Scholar
  • 26 Piert M, Machulla HJ, Becker G. et al . Dependency of the [18F]fluoro-misonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver.  Nucl Med Biol. 2000;  27 693-700
    CrossrefPubMedGoogle Scholar
  • 27 Piert M, Machulla HJ, Reischl G. et al . Fluorine-18 labeled fluoroazomycin arabinoside (FAZA): Imaging murine tumor hypoxia with improved biokinetics.  J Nucl Med. 2002;  43 278P
    PubMedGoogle Scholar
  • 28 Piert M, Machulla HJ, Picchio M. et al . Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside.  J Nucl Med. 2005;  46 106-113
    PubMedGoogle Scholar
  • 29 Procissi D, Claus F, Burgman P. et al . In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors.  Clin Cancer Res. 2007;  13 3738-3747
    CrossrefPubMedGoogle Scholar
  • 30 Rasey JS, Nelson NJ, Chin L. et al . Characteristics of the binding of labeled fluoromisonidazole in cells in vitro.  Radiat Res. 1990;  122 301-308
    CrossrefPubMedGoogle Scholar
  • 31 Rasey J, Koh W, Evans M. et al . Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.  Int J Radiat Oncol Biol Phys. 1996;  24 417-428
    PubMedGoogle Scholar
  • 32 Rasey JS, Casciari JJ, Hofstrand PD. et al . Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole.  Radiat Res. 2000;  153 84-92
    CrossrefPubMedGoogle Scholar
  • 33 Sorensen M, Horsman MR, Cumming P. et al . Effect of intratumoral heterogenity in oxygenation status on FMISO PET, autoradiography and eledrode pO2 measurements in murine tumors.  Int J Radiat Oncol Biol Phys. 2005;  62 854-861
    CrossrefPubMedGoogle Scholar
  • 34 Sorger D, Patt M, Kumar P. et al . [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors.  Nucl Med Biol. 2003;  30 317-326
    CrossrefPubMedGoogle Scholar
  • 35 Souvatzoglou M, Grosu A, Röper B. et al . Tumour Hypoxia Imaging with [18F]FAZA in Head and Neck Cancer Patients: A Pilot Study.  Eur J Nucl Med Mol Imaging. 2007;  34 1566-1575
    CrossrefPubMedGoogle Scholar
  • 36 Vaupel P, Schlenger K, Knoop C. et al . Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements.  Cancer Res. 1991;  51 3316-3322
    PubMedGoogle Scholar
  • 37 Zanzonico P, O’Donoghue J, Chapman JD. et al . Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.  Eur J Nucl Med Mol Imaging. 2004;  31 117-128
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse

Prof. Dr. R. Bares

Abteilung Nuklearmedizin

Radiologische Klinik

Universitätsklinikum Tübingen

Otfried-Müller-Str. 14

72076 Tübingen

Phone: +49/7071/29 82179

Fax: +49/7071/29 4601

Email: roland.bares@med.uni-tuebingen.de

      >